IgG4-Related Disease
81,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
  • Gebundenes Buch

IgG4-related disease is a new systemic disease that has only recently been identified and characterized. However, most clinical practitioners are not yet familiar with it and thus are likely to misdiagnose it. The purpose of this book is to raise awareness of this disease and its diagnostic pitfalls. A wealth of radiological and histopathological images helps clinicians to understand its characteristics in various organs as well as their clinical and basic medical backgrounds. All of the authors are experts who have published numerous important papers in the field. This book will be useful to…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
IgG4-related disease is a new systemic disease that has only recently been identified and characterized. However, most clinical practitioners are not yet familiar with it and thus are likely to misdiagnose it. The purpose of this book is to raise awareness of this disease and its diagnostic pitfalls. A wealth of radiological and histopathological images helps clinicians to understand its characteristics in various organs as well as their clinical and basic medical backgrounds. All of the authors are experts who have published numerous important papers in the field. This book will be useful to physicians in various disciplines such as gastroenterology, rheumatology, ophthalmology, otolaryngology, urology, hematology, and respiratory medicine, not only as a textbook but as an authoritative and comprehensive reference work as well.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
John H. Stone, MD, MPH is Clinical Director of Rheumatology, Harvard Medical School, Boston, MA, USA and the Chairman of the International Network for the Study of the Systemic Vasculitides (INSSYS). Dr Stone's research interests relate to translational investigations in systemic vasculitis. He has directed two multicenter clinical trials in Wegener's granulomatosis and antineutrophil cytoplasmic antibody-associated vasculitis, the Wegener's Granulomatosis Etanercept Trial (WGET) and the Rituximab in ANCA-associated Vasculitis (RAVE) trial. His other research efforts relate to the identification of new biomarkers through proteomic approaches, and to the development of clinical trials' outcome measures in rheumatic autoimmune diseases